Drugmakers Hold Back Swiss Reimbursement Applications Amid Pricing Concerns

Pharmaceutical companies are increasingly delaying applications for health-insurance reimbursement for new medicines in Switzerland, raising concerns about patient access to innovative treatments. A survey by Swiss pharmaceutical industry association Interpharma found that seven of 22 innovative medicines introduced between January 2025 and June 2026 were not submitted for inclusion on Switzerland’s mandatory health-insurance reimbursement list. […]

Continue Reading

Global Drugmakers Commit Hundreds of Billions to Expand U.S. Manufacturing

Major pharmaceutical companies are significantly expanding their manufacturing and research presence in the United States, with companies including Pfizer, Eli Lilly, Johnson & Johnson, Roche, AstraZeneca and Novartis announcing investments that together approach $500 billion. The investments cover new manufacturing facilities, research and development centers, supply-chain infrastructure and expansions of existing sites. The moves come […]

Continue Reading